Skip to main content

Table 2 Criteria driving therapeutic decisions at baseline

From: Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial

Criteria driving therapeutic decisions at baseline

Hizentra

N = 117

Disease-related

 Type of infectious agent, n (%)

51 (43.6 %)

 Neutropenia, n (%)

11 (9.4 %)

 Stage of disease, n (%)

39 (33.3 %)

 Last gammaglobulin titer, n (%)

67 (57.3 %)

 Other, n (%)

21 (17.9 %)

Treatment-related

 Ease of administration, n (%)

80 (68.4 %)

 Volume of injection, n (%)

76 (65.0 %)

 Other, n (%)

8 (6.8 %)

Patient-related

 Poor venous access, n (%)

24 (20.5 %)

 Poor tolerance to IVs, n (%)

9 (7.7 %)

 Difficult hospital access, n (%)

38 (32.5 %)

 Busy schedule, n (%)

23 (19.7 %)

 Importance of being independent, n (%)

71 (60.7 %)

 Associated comorbidities, n (%)

15 (12.8 %)

 Age, n (%)

42 (35.9 %)

 Recurrence of infection over the previous 12 months, n (%)

26 (22.2 %)

 Recurrence of infection over the previous 3 years, n (%)

24 (20.5 %)

 Satisfactory renal function, n (%)

13 (11.1 %)

 Other, n (%)

5 (4.3 %)

Additional considerations

 Physician and department experience

84 (71.8 %)

 Staff decision

24 (20.5 %)

 Failure of previous prophylactic measures

20 (17.1 %)

 Other

7 (6.0 %)

  1. IV intravenous therapy